Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience

We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin’s lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug–drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.

Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema

Purpose. In this study, we describe a new surgical technique for the treatment of refractory DME. The technique consists of vitrectomy with ILM peeling with a subretinal injection of ranibizumab. Methods. This is a prospective interventional noncomparative study including patients with refractory DME. Included patients were subjected to the new surgical technique of pars plana vitrectomy with subretinal injection of ranibizumab. Results. The study included 19 eyes with refractory macular edema, in which this novel technique was attempted. There were 10 males and 9 females. The age of the patients ranged from 17 to 67 years with a mean of 55.58 ± 13.242 years. The duration of diabetes before enrollment in the study ranged from 7 to 25 years with a mean of 16.3 years. Preoperatively, the mean CMT of the eyes ranged from 352 to 883 microns with mean ± SD of 498.58 ± 152.16 microns. Postoperatively, this improved significantly to 373.5 ± 100.3, 355.9 ± 89.8, and 365.74 ± 120.12 microns at 1, 3, and 6 months, respectively (p≤0.001 for all). Conclusion. This novel surgical procedure of vitrectomy with ILM peeling with a subretinal injection of ranibizumab is effective in cases of refractory DME. The study has been registered in Contact ClinicalTrials.gov PRS Identifier: NCT03975088.

Oral Azithromycin Pulse Therapy and Daily Topical Adapalene in the Treatment of Acne Vulgaris: An Open Randomized Noncomparative Study

The safety and efficacy of oral azithromycin and topical adapalene are well documented. In this study, concomitant use of oral azithromycin pulse therapy and daily topical adapalene in the treatment of acne vulgaris is assessed. A total of 37 patients fulfilled the inclusion criteria were enrolled. Azithromycin, 500 mg orally once daily first 3 days of 10 days' cycle for 9 cycle & topical Adapalene (0.5%) at night. Patients evaluated at 4 weeks' interval by using Michaelsson acne severity index. The overall assessment was made by percent reduction of acne lesions and severity score. At the end of 12 weeks' treatment 99.8% of comedones, 98.7% papular lesion, 94.3% pustular lesion and 88.8% infiltrated lesion were cleared. Only 2.9% cystic lesion responded to the regimens. Percent reduction of Michaelsson acne severity index was 87%, which was statistically highly significant. Overall assessment revealed acne lesion cleared in 22% cases, excellent improvement observed in 65% and 13% showed good response. Adverse effect was minimal. So, azithromycin pulse therapy and topical adapalene is indeed effective and safe in the treatment of acne vulgaris.Medicine Today 2016 Vol.28(2): 52-56

Experience with the carbamylated monomeric allergoid Lais® for sublingual immunotherapy in patients with grass pollen or mite-induced allergic rhinoconjunctivitis

The article presents the results of a prospective noncomparative study of carbamylated monomeric allergoid Lais ® for sublingual immunotherapy (SLIT) in patients with allergic rhinoconjunctivitis caused by pollen grasses. We suggest that SLIT using Lais ® sublingual tablets is an effective and well-tolerated method of treatment.

Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema

Purpose: To evaluate the efficacy and safety of intravitreal implant of dexamethasone (Ozurdex®) in diabetic macular edema (DME). Methods: This was a retrospective multicenter noncomparative study. Seventy-eight patients with DME followed for at least 6 months were included (P1.5 Network). Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP) and cataract progression were studied at baseline and then at 1, 2, 4 and 6 months. Results: The mean CRT decrease from baseline was 145.2 µm at 6 months. The mean BCVA improvement from baseline was 6.7 at 6 months. An increase in IOP was observed for 11.7% of patients, and all patients were managed by topical treatment. No glaucoma or cataract surgery was necessary, and no endophthalmitis was reported. Conclusions: One injection of Ozurdex has an anatomical and functional effectiveness for the treatment of DME. Side effects were rare and manageable in our practice.